Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chongqing Zhifei Biological Products Co (SZSE:300122) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chongqing Zhifei Biological Products Co EBITDA Margin % Related Terms
Chongqing Zhifei Biological Products Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Zhifei Biological Products Co EBITDA Margin % Chart
Chongqing Zhifei Biological Products Co Annual Data
SZSE:300122 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Chongqing Zhifei Biological Products Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Zhifei Biological Products Co EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Zhifei Biological Products Co (SZSE:300122) has a EBITDA Margin % of -16.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chongqing Zhifei Biological Products Co and its competitors. According to the industry distribution chart, Chongqing Zhifei Biological Products Co ranks #587 out of 942 companies in the Biotechnology industry, placing it in the top 62.3%.
Is Chongqing Zhifei Biological Products Co's EBITDA Margin % too high?
Chongqing Zhifei Biological Products Co's current EBITDA Margin % is -16.70%. Based on the distribution chart, Chongqing Zhifei Biological Products Co ranks #587 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chongqing Zhifei Biological Products Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chongqing Zhifei Biological Products Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chongqing Zhifei Biological Products Co ranks #587 out of 942 companies for EBITDA Margin %. This places Chongqing Zhifei Biological Products Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chongqing Zhifei Biological Products Co and its competitors. Chongqing Zhifei Biological Products Co's current EBITDA Margin % is -16.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Zhifei Biological Products Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Zhifei Biological Products Co (SZSE:300122) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.99, compared to a current price of ¥14.25 — trading 1.9% above its estimated fair value. The current EBITDA Margin % is -16.70%. Chongqing Zhifei Biological Products Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chongqing Zhifei Biological Products Co (SZSE:300122), the current EBITDA Margin % is -16.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chongqing Zhifei Biological Products Co (SZSE:300122) Overvalued in 2026?
Based on GuruFocus' analysis, Chongqing Zhifei Biological Products Co stock appears to be overvalued.
The current stock price of ¥14.25 is trading 1.9% above its estimated GF Value™ of ¥13.99.
GuruFocus considers Chongqing Zhifei Biological Products Co to be Fairly Valued.
Key valuation signals for SZSE:300122:
EBITDA Margin %: -16.70%
GF Value™: ¥13.99 vs. price of ¥14.25 (1.9% above fair value)
No single metric tells the full story. See the SZSE:300122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chongqing Zhifei Biological Products Co Ltd is engaged in research and development, production, and sales of vaccines and biological products. The company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevention and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus, and other viruses, general drugs and other biological products, among others.
65GF Score
Get the complete analysis for SZSE:300122
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300122 has been successfully added to your 
